Search

everythinglearnresearchcommunity

for

Search:↓

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Ruxolitinib can cause a delayed skin reaction on the nose.

Higher RBP4 levels are linked to severe alopecia areata, but genetic variant rs3758539 doesn't affect baricitinib response.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

Baricitinib improved hair loss and arthritis in a lupus patient.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Topical eye β-blockers might cause hair loss, which usually gets better after stopping the medication.

Allergic reactions to blood thinners are rare but can be serious, requiring careful testing and alternative treatments.

Gefitinib can cause rare scarring hair loss.

CS12192 effectively treats alopecia areata with better safety than current options.

JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.

Valproic acid and rapamycin protect hair follicle stem cells from damage by activating a protective pathway.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

The inhibitor affects androgen metabolism but not ovarian function.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Tofacitinib helped a patient regrow hair after 40 years of total hair loss.

Reducing gefitinib dosage improved hair loss, but scarring remained.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Sorafenib can cause delayed skin problems, so patients need careful monitoring.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.